WINGMEN Trial Data Now Available on Oxford Cancer Translational Data Platform

Data from the WINGMEN clinical trial is now available on the Oxford Cancer Translational Data Platform (TDP). WINGMEN is a Phase 0 study investigating the insulin-like growth factor (IGF) antibody Xentuzumab in men with prostate cancer.

The trial was run by the Oncology Clinical Trials Office and led by Professor Simon Lord. It recruited participants in the three to four-week window prior to their scheduled radical prostatectomy, providing a unique opportunity to study treatment effects in the pre-operative setting. The primary aims of WINGMEN were to assess the feasibility of recruiting men with early prostate cancer, evaluate the tolerability of Xentuzumab before surgery, and generate matched pre- and post-treatment samples for detailed molecular and tissue-based analyses. The study enrolled 27 men.

WINGMEN joins a wider portfolio of trials hosted on the Translational Data Platform, which together comprise clinical, molecular and imaging data from more than 1,100 trial participants across five studies. All datasets are carefully curated, quality-controlled and harmonised, and can be easily explored, visualised and analysed either independently or with support from the TDP team. Researchers interested in accessing WINGMEN or other datasets on the platform can contact the TDP team for further information.